Skip to main content
. 2009 Jul 8;9:222. doi: 10.1186/1471-2407-9-222

Table 2.

QLQ – C30 & BR -23 unadjusted scale scores, percentage of subjects with problems & in good conditiona.

Variables N No. of
items
Mean (SD) 95% C.I. % scoring < 33.3%c % scoring ≥ 66.7%c
C-30 Functional scalesb
Global QOL/general health 340 2 45.3(15.3) 43.7 – 46.9 6.2 10.9
Physical functioning 330 5 52.6(18.8) 50.6 – 54.6 11.2 25.2
Role functioning 340 2 55.1(21.4) 52.7 – 57.5 7.6 39.1
Emotional 323 2 60.3(22.5) 57.7 – 62.9 8.4 45.2
Cognitive 342 4 59.9(23.9) 57.3 – 62.5 5.8 51.2
Social 339 2 61.2(22.7) 58.8 – 63.6 6.5 52.8
C – 30 symptoms/scalesc
Fatigue 331 3 38.9(21.3) 36.5 – 41.3 29.0 13.6
Nausea & vomiting 334 2 30.2(24.5) 27.6 – 32.8 48.5 12.0
Pain 334 2 43.8(21.7) 41.4 – 46.2 20.1 27.5
Dyspnoea 335 1 42.4(27.8) 39.4 – 45.4 18.8 40.0
Sleep disturbance 338 1 42.7(28.2) 39.7 – 45.7 18.3 39.3
Appetite loss 339 1 37.5(28.0) 34.5 – 40.5 25.1 32.7
Constipation 345 1 27.8(28.2) 24.8 – 30.8 42.0 22.0
Diarrhea 343 1 22.1(27.5) 19.1 – 25.1 54.8 19.2
Financial impact 344 1 31.2(25.2) 28.4 – 34.0 29.1 19.8
QOL – BR23: Functional scalesb
Body image 299 4 61.8(23.3) 59.0 – 64.6 7.0 47.8
Sexual functioning 303 2 69.9(23.6) 67.1 – 72.7 1.3 68.0
Sexual enjoyment 221 1 61.5(23.0) 58.3 – 64.7 2.3 70.1
Future perspective 334 1 59.5(31.9) 56.1 – 62.9 11.7 64.7
BR23: Symptom scalesc
Systemic side effects 300 7 40.1(17.5) 38.1 – 42.1 29.3 6.7
Breast symptoms 293 4 35.6(25.4) 32.6 – 38.6 42.3 14.3
Arm symptoms 318 3 38.2(23.4) 35.6 – 40.8 33.0 13.8
Upset by hair loss 331 1 44.8(29.6) 41.6 – 48.0 17.2 40.8

aFor functional scales, subjects scoring < 33.3% have problems; those scoring ≥ 66.7% have good functioning. For symptom scales/symptoms, subjects scoring < 33.3% have good functioning; those scoring = 66.7% have problems

b For functional scales, higher scores indicate better functioning

c For symptom scales, higher scores indicate worse functioning